-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
Review
(2864) Views (488) Full article downloads
Authors: George P Kim, Axel Grothey
Published Date June 2008
Volume 2008:2(2) Pages 223 - 228
DOI: http://dx.doi.org/10.2147/BTT.S1980
George P Kim, Axel Grothey
College of Medicine, Mayo Clinic
Abstract: The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can succeed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment.
Keywords: colorectal cancer, chemotherapy, panitumumab, oxaliplatin, irinotecan, bevacizumab, cetuximab
Readers of this article also read:
Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents
Natalizumab in the treatment of Crohn’s disease
α-L-iduronidase therapy for mucopolysaccharidosis type I
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
Therapeutic vaccines for malignant brain tumors
Palliative treatment of malignant ascites: profile of catumaxomab
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Erratum
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
